Drug Trial Radar · NCT07947732
Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2028
Study completion May 2032
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drugs lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) to assess how it is absorbed, modified, distributed and eliminated from the body of young people (the pharmacokinetics (PK) parameters of the drugs). It will also check the safety, and tolerability of LEN in combination with TAB, and ZAB in participants living with human immunodeficiency virus type 1 (HIV-1). The primary objectives of this study are to evaluate the PK parameters, safety, and tolerability of LEN, TAB, and ZAB.
Conditions
- HIV-1-infection
Interventions
Lenacapavir TabletDrug
Administered orally
Lenacapavir InjectionDrug
Administered SC
TeropavimabDrug
Administered IV
ZinlirvimabDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) parameters: Ctrough for LEN During the First Dosing Cycle (Day 1 to Week 26)Time frame: Day 1 to Week 26
- Pharmacokinetics (PK) parameters: Ctrough for TAB During the First Dosing Cycle (Day 1 to Week 26)Time frame: Day 1 to Week 26
- Pharmacokinetics (PK) parameters: Ctrough for ZAB During the First Dosing Cycle (Day 1 to Week 26)Time frame: Day 1 to Week 26
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26Time frame: First dose date up to Week 26
- Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 26Time frame: First dose date up to Week 26
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jacobi Medical Center
The Bronx, New York
AXCES Research Group, LLC
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.